- IPO window opens for Editas, others
- Gilead earnings and outlook draw usual scrutiny
- Martin Shkreli and Turing grilled by Congress
- Comments from FDA leadership on generics, biosimilars, drug prices
- As seen on the stream (the best of everything else new and noteworthy, including a taste of the sentiment among biotech investors)
Biotech Tweets of the Week (February 1-5, 2016)
$AAVL $ACAD $ADAP $AGN $AVXS $AXON $BGNE $BLUE $CEMP $EDIT $GILD $ICPT $JUNO $KITE $ONCE $PETX $PFE $PTI $SRPT $VRTX $VRX $XBI $IBB
FDA, biosimilars, drug pricing, opioids, biotech market sentiment, cancer moon shot, CRISPR, IPOs